Maverick Capital’s CARGO Therapeutics CRGX Stock Holding History

Maverick Capital’s Portfolio CRGX Stock Details CRGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400,000	Closed	-$9.26M	–	439
2023 Q4	$9.26M	Buy	+400,000	New	+$6.78M	0.19%	54

Other funds holding CRGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Maverick Capital's CRGX Position: Q1 2024 in Review

Maverick Capital sold out of CARGO Therapeutics (CRGX) in Q1 2024, closing a stake of 400,000 shares — an estimated $9.26M sold.

Maverick Capital first reported a position in CRGX in Q4 2023 and held it in 1 quarter. The position peaked at $9.26M in Q4 2023. 65 funds tracked by Wall St. Rank hold CRGX as of Q1 2024.

Maverick Capital reported no remaining CARGO Therapeutics position as of Q1 2024 after selling out during the quarter.
Maverick Capital sold 400,000 CARGO Therapeutics shares in Q1 2024, an estimated $9.26M.
Maverick Capital first reported a position in CARGO Therapeutics in Q4 2023 and held it in 1 quarter.
Maverick Capital's CARGO Therapeutics position peaked at $9.26M in Q4 2023.
65 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q1 2024.

Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.